Yunku Yeu

Yunku Yeu

Auto-generated profile, based on publicly available information

Yunku Yeu

Yonsei University, Seoul, South Korea

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
RTRubina Tuladhar
Rubina Tuladhar
YYYunku Yeu
Yunku Yeu
JPJohn Tyler Piazza
John Tyler Piazza
ZTZhen Tan
Zhen Tan
JCJean Rene Clemenceau
Jean Rene Clemenceau
LLLawrence Lum
Lawrence Lum
The introduction of insertion-deletions (INDELs) by non-homologous end-joining (NHEJ) pathway underlies the mechanistic basis of CRISPR-Cas9-directed genome editing. Selective gene ablation using CRISPR-Cas9 is achieved by installation of a premature termination codon (PTC) from a frameshift-inducing INDEL that elicits nonsense-mediated decay (NMD) of the mutant mRNA. Here, by examining the mRNA and protein products of CRISPR targeted genes in a cell line panel with presumed gene knockouts, we detect the production of foreign mRNAs or proteins in ~50% of the cell lines. We demonstrate that these aberrant protein products stem from the introduction of INDELs that promote internal ribosomal entry, convert pseudo-mRNAs (alternatively spliced mRNAs with a PTC) into protein encoding molecules, or induce exon skipping by disruption of exon splicing enhancers (ESEs). Our results reveal challenges to manipulating gene expression outcomes using INDEL-based mutagenesis and strategies useful in mitigating their impact on intended genome-editing outcomes.

15 May 2015 in Molecular BioSystems
Verified
Journal Article
Closed access
PDF file
YYYunku Yeu
Yunku Yeu
YYYoungmi Yoon
Youngmi Yoon
SPSanghyun Park
Sanghyun Park
Identifying alternative indications for known drugs is important for the pharmaceutical industry. Many computational methods have been proposed for predicting unknown associations between drugs and target proteins associated with diseases. To produce better prediction, researchers should not only develop accurate algorithms but identify good features that reflect intracellular systems. In this paper, we proposed a novel method for exploiting protein localization. We generated localization vectors (LVs) from protein localization and propagated LVs through a protein interaction network to increase the coverage of the localization information. The LVs showed distinct patterns among targets of known drugs as well as independent characteristics compared to existing features. Based on the experimental results, we determined that including LVs improves cross-validation accuracy and, produces better novel predictions with real and independent clinical trial data. Moreover, the propagation of LVs showed a positive result that it can help in increasing the coverage of the prediction results.

8 April 2020 in Cancer Research
Verified
Journal Article
Open access
PDF file
SWSam C. Wang
Sam C. Wang
YYYunku Yeu
Yunku Yeu
SHSuntrea T.G. Hammer
Suntrea T.G. Hammer
SXShu Xiao
Shu Xiao
MZMin Zhu
Min Zhu
MPMatthew R. Porembka
Matthew R. Porembka
Hispanic/Latino patients have a higher incidence of gastric cancer and worse cancer-related outcomes compared with patients of other backgrounds. Whether there is a molecular basis for these disparities is unknown, as very few Hispanic/Latino patients have been included in previous studies. To determine the genomic landscape of gastric cancer in Hispanic/Latino patients, we performed whole-exome sequencing (WES) and RNA sequencing on tumor samples from 57 patients; germline analysis was conducted on 83 patients. The results were compared with data from Asian and White patients published by The Cancer Genome Atlas. Hispanic/Latino patients had a significantly larger proportion of genomically stable subtype tumors compared with Asian and White patients (65% vs. 21% vs. 20%, P < 0.001). Transcriptomic analysis identified molecular signatures that were prognostic. Of the 43 Hispanic/Latino patients with diffuse-type cancer, 7 (16%) had germline variants in CDH1. Variant carriers were significantly younger than noncarriers (41 vs. 50 years, P < 0.05). In silico algorithms predicted five variants to be deleterious. For two variants that were predicted to be benign, in vitro modeling demonstrated that these mutations conferred increased migratory capability, suggesting pathogenicity. Hispanic/Latino patients with gastric cancer possess unique genomic landscapes, including a high rate of CDH1 germline variants that may partially explain their aggressive clinical phenotypes. Individualized screening, genetic counseling, and treatment protocols based on patient ethnicity and race may be necessary.Significance: Gastric cancer in Hispanic/Latino patients has unique genomic profiles that may contribute to the aggressive clinical phenotypes seen in these patients.

21 January 2021 in Cancers
Verified
Journal Article
Open access
PDF file
JKJeonghyun Kang
Jeonghyun Kang
JLJae-Hoon Lee
Jae-Hoon Lee
HLHye Sun Lee
Hye Sun Lee
ECEun-Suk Cho
Eun-Suk Cho
EPEun Jung Park
Eun Jung Park
THTae Hyun Hwang
Tae Hyun Hwang
The aim of this study was to investigate the prognostic value of radiomics signatures derived from 18F-fluorodeoxyglucose (18F-FDG) positron-emission tomography (PET) in patients with colorectal cancer (CRC). From April 2008 to Jan 2014, we identified CRC patients who underwent 18F-FDG-PET before starting any neoadjuvant treatments and surgery. Radiomics features were extracted from the primary lesions identified on 18F-FDG-PET. Patients were divided into a training and validation set by random sampling. A least absolute shrinkage and selection operator Cox regression model was applied for prognostic signature building with progression-free survival (PFS) using the training set. Using the calculated radiomics score, a nomogram was developed, and its clinical utility was assessed in the validation set. A total of 381 patients with surgically resected CRC patients (training set: 228 vs. validation set: 153) were included. In the training set, a radiomics signature labeled as a rad_score was generated using two PET-derived features, such as gray-level run length matrix long-run emphasis (GLRLM_LRE) and gray-level zone length matrix short-zone low-gray-level emphasis (GLZLM_SZLGE). Patients with a high rad_score in the training and validation set had a shorter PFS. Multivariable analysis revealed that the rad_score was an independent prognostic factor in both training and validation sets. A radiomics nomogram, developed using rad_score, nodal stage, and lymphovascular invasion, showed good performance in the calibration curve and comparable predictive power with the staging system in the validation set. Textural features derived from 18F-FDG-PET images may enable detailed stratification of prognosis in patients with CRC.

1 December 2013 in Computers in Biology and Medicine
Verified
Journal Article
Closed access
JAJaegyoon Ahn
Jaegyoon Ahn
YYYoungmi Yoon
Youngmi Yoon
YYYunku Yeu
Yunku Yeu
HLHookuen Lee
Hookuen Lee
SPSanghyun Park
Sanghyun Park

11 July 2018 in Cancer Reports
Verified
Journal Article
Open access
PDF file
ESEmily Kunce Stroup
Emily Kunce Stroup
YYYunku Yeu
Yunku Yeu
ABAlbert Budhipramono
Albert Budhipramono
THTae Hyun Hwang
Tae Hyun Hwang
DRDinesh Rakheja
Dinesh Rakheja
KCKenneth Chen
Kenneth Chen
Background: Wilms tumor and rhabdoid tumor can have similar clinical presentations, but they have distinct histological and biological features. For instance, Wilms tumors commonly bear mutations in kidney differentiation or microRNA processing genes, whereas rhabdoid tumor is characterized by loss of SMARCB1.Aims: We initially set out to characterize and identify tumor suppressor microRNAs in WT‐CLS1, which had been described as a Wilms tumor cell line.Methods and Results: We characterized the cell line WT‐CLS1 by whole exome sequencing, RNA‐seq, and xenograft histology. We measured the effect of microRNA overexpression on WiT49, WT‐CLS1, BT‐12, and CHLA‐06‐ATRT.We found that miR‐16 significantly impairs cell proliferation in WT‐CLS1 by repressing numerous cell cycle genes, including the D‐type cyclins. In addition, we found that the WT‐CLS1 cell line demonstrates the classic histological, mutational, and transcriptional hallmarks of rhabdoid tumor, including SMARCB1 loss. Lastly, miR‐16 also represses cell cycle genes and impairs proliferation in the BT‐12 and CHLA‐06‐ATRT rhabdoid tumor cell lines.Conclusions: The loss of SMARCB1 warrants reclassification of WT‐CLS1 as rhabdoid tumor. Overexpression of miR‐16 significantly abrogates proliferation of WT‐CLS1 and other rhabdoid tumor cell lines. Further studies are necessary to gain insight into the potential for miR‐16 to be a tumor suppressor or a novel therapeutic in rhabdoid tumor.